The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.

MLA

Gravina, Giovanni Luca, et al. “The Brain-Penetrating CXCR4 Antagonist, PRX177561, Increases the Antitumor Effects of Bevacizumab and Sunitinib in Preclinical Models of Human Glioblastoma.” Journal of Hematology & Oncology, vol. 10, Jan. 2017, pp. 1–16. EBSCOhost, https://doi.org/10.1186/s13045-016-0377-8.

APA

Gravina, G. L., Mancini, A., Marampon, F., Colapietro, A., Monache, S. D., Sferra, R., Vitale, F., Richardson, P. J., Patient, L., Burbidge, S., & Festuccia, C. (2017). The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma. Journal of Hematology & Oncology, 10, 1–16. https://doi.org/10.1186/s13045-016-0377-8

Chicago

Gravina, Giovanni Luca, Andrea Mancini, Francesco Marampon, Alessandro Colapietro, Simona Delle Monache, Roberta Sferra, Flora Vitale, et al. 2017. “The Brain-Penetrating CXCR4 Antagonist, PRX177561, Increases the Antitumor Effects of Bevacizumab and Sunitinib in Preclinical Models of Human Glioblastoma.” Journal of Hematology & Oncology 10 (January): 1–16. doi:10.1186/s13045-016-0377-8.